OGT’s Cytocell portfolio available via Sysmex in China and Spain

Monday 6 July 2020
Product types:

Oxford, UK – 06 July 2020. Oxford Gene Technology (OGT), A Sysmex Group Company, has today announced that from 1st July 2020, Cytocell® customers in China and Spain will be able to benefit from the established, comprehensive sales and support services of Sysmex. This significant addition to direct sales of Cytocell fluorescence in situ hybridisation (FISH) products demonstrates the extensive collaboration between OGT and Sysmex, as well as the continuing strategy to reinforce this—further expansions across the entire OGT portfolio are planned in the current financial year.

The expansion involves Sysmex Shanghai, Sysmex Hong Kong and Sysmex Espana. Customers in China will continue to be able to use the current Cytocell distributor, Youning Biotech, however, the addition of Sysmex Shanghai offers broader coverage of the market through a larger commercial organisation – providing OGT with improved access to the Chinese market via the existing Sysmex Shanghai sales team and its extensive network of distributors. Sysmex Espana will be the country’s sole distributor for Cytocell products.

OGT’s Cytocell brand offers the widest range of FISH probes on the market and is well known and respected for its high-quality, reliability and cost-effectiveness as well as its renowned customer support, service and expertise. When purchasing probes via Sysmex, users benefit from all this, as well as the vast reach and reputation that Sysmex has in their established markets.

Commenting on the announcement, Gareth Thomson, Executive VP sales at OGT said: “We’re very pleased to announce these new collaborations with Sysmex Group companies. It builds on a series of success stories in other territories where we work with Sysmex’s distribution network. It provides us with an excellent opportunity to grow significantly in these territories benefitting from the established relationships with major customers in the regions.”

OGT’s CEO, John Anson, added: “Today’s announcement also highlights the wider strengthening of our relationship with Sysmex that goes beyond sales and distribution. OGT became part of Sysmex Group three years ago and since then we’ve been seeing ever-closer collaboration in other parts of the company as well—for example in the development of new products for next generation sequencing.”

OGT is also working towards expanding direct sales in certain territories of its CytoSure™ cytogenetics and rare disease, and SureSeq™ cancer NGS portfolios.

 For more information please visit www.cytocell.com/contact


For further information, please contact:

Oxford Gene Technology, Begbroke Science Park, Begbroke Hill, Woodstock Road, Begbroke, Oxfordshire, OX5 1PF, U.K.

T: +44 (0) 1865 856800 ; F: +44 (0) 1865 848684

E: contact@ogt.com ; W: www.ogt.com ; Twitter: @OxfordGeneTech


Editor’s notes

About Oxford Gene Technology

Oxford Gene Technology (OGT) provides world-class genetics research solutions to leading clinical and academic research institutions. Founded by Professor Sir Edwin Southern, and with customers in over 60 countries worldwide, OGT has a strong reputation and increasing share in the large and growing genomic medicine market. The Company’s Cytocell®, CytoSure™ and SureSeq™ range of fluorescence in situ hybridisation (FISH), microarray and next generation sequencing (NGS) products deliver high-quality genetic analysis, enabling accurate identification and confirmation of the causative variation underlying genetic disease. OGT was acquired by Sysmex Corporation (Sysmex), a Japanese in vitro diagnostic company in June 2017. The acquisition of OGT expands Sysmex’s life science business and reinforces its initiatives towards personalised medicine.

For more information on the Company, please visit our website at www.ogt.com

CytoSure™, SureSeq™ and myProbes®: For Research Use Only, not for use in diagnostic procedures. Cytocell: Some products may not be available in your region.

About Sysmex Corporation

Sysmex Corporation is a world leader in clinical laboratory systemization and solutions, including laboratory diagnostics, laboratory automation and clinical information systems. Serving customers for more than 50 years, Sysmex focuses on technological leadership in diagnostic science and information tools that make a difference in the health of people worldwide. The company is also exploring emerging opportunities in the life science field. Its R&D efforts focus on the development of high-value-added testing and diagnostic technologies that are innovative, original and optimize individual health. Sysmex also seeks to leverage its state-of-the-art technologies for cell, gene and protein analysis. The company, headquartered in Kobe, Japan, has subsidiaries in North America, Latin America, Europe, the Middle East, Africa, China and Asia Pacific and employs more than 9,000 employees worldwide. Sysmex Corporation is listed in the top tier of the Tokyo Stock Exchange.

For more information about Sysmex Corporation and its affiliate companies, please visit www.sysmex.co.jp/en/.